Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 701–800 of 1,000
Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review
Naik, P. P. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00583-z · Cited by 18
Martins, C. P., Silva, M. C., Rasbach, E., Singh, P. K., Itoh, Y., Williams, J. B., Statham, E., Meurer, A., Martinez, D. V., Brandenburg, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16776-1 · Cited by 18
Zhou, Y., Yang, Q., Dong, Y., Ji, T., Zhang, B., Yang, C., Zheng, S., Tang, L., Zhou, C., Qian, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2470 · Cited by 19
Dasyam, N., SHARPLES, K. J., Barrow, C., Huang, Y., Bauer, E., Mester, B., Wood, C. E., Authier-Hall, A., Dzhelali, M., Ostapowicz, T., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03400-y · Cited by 17
Chen, L., Zheng, X. W., Huang, H., Chen, F., Wu, S., Chen, R., Jiang, H., Yuan, M., Fu, Y., Ying, H., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110786 · Cited by 17
Bai, X. L., Lawless, A. R., Czapla, J., Gerstberger, S. C., Park, B. J., Jung, S., Johnson, R. R., Yamazaki, N., Ogata, D., Umeda, Y., et al. (2024) · JAAD International · doi:10.1016/j.jdin.2023.11.014 · Cited by 17
Self-citationvan Akkooi, A. C. J., Mandalà, M., Nathan, P., Haydon, A. M., Postow, M. A., & Rutkowski, P. L. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100021 · Cited by 17
Self-citationGarutti, M., Bruno, R., Polesel, J., Pizzichetta, M. A., & Puglisi, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32433 · Cited by 19
Moutafi, M. K., Bates, K., Aung, T. N., García-Milian, R., Xirou, V., Vathiotis, I. A., Gavrielatou, N., Angelakis, A., Schalper, K. A., Salichos, L., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009039 · Cited by 19
Jurlander, R. S., Guldbrandt, L. M., Holmstroem, R. B., Madsen, K. S., Donia, M., Haslund, C. A., Schmidt, H., Bastholt, L., Ruhlmann, C. H. B., Svane, I. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115053 · Cited by 20
Cardiotoxicity associated with immune checkpoint inhibitors: Systematic review and meta-analysis
Piazza, L., Carollo, A., Martino, E. D., Novara, M. E., Cutaia, S., Provenzani, A., & Rizzo, S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104587 · Cited by 17
Najjar, Y. G., Puligandla, M., Lee, S. J., & Kirkwood, J. M. (2019) · Cancer · doi:10.1002/cncr.32162 · Cited by 17
“Missing data 30 (10) 7 (1) 54 (6) 0 (0) 91 (5) Lactate dehydrogenase Abnormal 40 (14) 46 (7) 187 (21) 5 (5) 278 (15) Normal 193 (67) 562 (88) 597 (68) 101 (94) 1453 (76) Missing data 53 (19) 34 (5) 93 (11) 1 (1) 181 (9)”
The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00231 · Cited by 18
Bioactive lipids as modulators of immune check point inhibitors
Das, U. N. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109473 · Cited by 18
Kuriyama, K., Higuchi, T., Yokobori, T., Saito, H., Yoshida, T., Hara, K., Suzuki, S., Sakai, M., Sohda, M., Higuchi, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14421 · Cited by 19
Miyashita, H., Mikami, T., Satoi, S., Cruz, C., & Galsky, M. D. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000339 · Cited by 17
Jia, D., Niu, Y.-L., Zhu, H., Wang, S., Ma, T., & Li, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675873 · Cited by 19
“org 6 The median RFSPem in this study was shorter compared to the KEYNOTE-054 trial, in which the patients had either stage IIIA, or IIIB or IIIC melanoma with no in-transit metastases (25).”
ResultLi, J., Wang, J., Li, D., Wen, X., Ding, Y., Liu, X., Jiang, H., Huang, F., & Zhang, X. (2021) · Dermatologic Therapy · doi:10.1111/dth.15067 · Cited by 19
“Furthermore, no one discontinued adjuvant PD-1 inhibitor due to treatmentrelated toxicity, and no treatment-related deaths occurred.(6,7) And the adverse events recorded in the anti-PD-1 group was almost early toxicity that occurred during administration and within 6 months after drug withdrawal.”
BackgroundMulder, E. E. A. P., Smit, L., Grünhagen, D. J., Verhoef, C. K., Sleijfer, S., van der Veldt, A. A. M., & Groot, C. A. U.-D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100303 · Cited by 18
“Third, according to CEA guidelines, AEs were not included as no grade 3-4 AEs exceeded the threshold of 5% incidence.(16-18) Whereas the impact of AEs on ICERs is considered to be limited, patients suffer from these AEs, which can be lifelong and sometimes require lifelong therapy such as hormone replacement.”
BackgroundMethodInfluentialAmabile, S., Roccuzzo, G., Pala, V., Tonella, L., Rubatto, M., Merli, M., Fava, P., Ribero, S., Fierro, M. T., Queirolo, P., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235475 · Cited by 17
Moncrieff, M. D., Lo, S., Scolyer, R. A., Heaton, M. J., Nobes, J. P., Snelling, A. P., Carr, M. J., Nessim, C., Wade, R. G., Peach, A. H. S., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11761-4 · Cited by 17
“Recently, several, prospective, randomized, controlled trials have shown clinical benefit of adjuvant systemic therapy, in terms of recurrence-free survival, for patients with metastatic melanoma.(7,25,26) As a result, most modern clinical guidelines recommend it for high-risk resected metastatic melanoma.”
BackgroundChye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17
de Meza, M. M., Blokx, W. A. M., Bonenkamp, J. J., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Boers‐Sonderen, M. J., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., et al. (2023) · Cancers · doi:10.3390/cancers15020409 · Cited by 17
“In contrast, adjuvant anti-PD-1 treatment was approved and reimbursed in December 2018 [3,4].”
BackgroundSelf-citationThe Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma
Hieken, T. J., Kane, J. M., & Wong, S. L. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6812-z · Cited by 17
Immune checkpoint inhibitor myocarditis
Raikhelkar, J., & Uriel, N. Y. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000622 · Cited by 17
Dillman, R. O., Cornforth, A. N., McClay, E. F., & DePriest, C. B. (2019) · Melanoma Management · doi:10.2217/mmt-2018-0010 · Cited by 19
Mowery, Y. M., Patel, K. R., Chowdhary, M., Rushing, C. N., Choudhury, K. R., Lowe, J. R., Olson, A. C., Wisdom, A. J., Salama, J. K., Hanks, B. A., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.06.013 · Cited by 17
“Anti-PD-1 based therapies are a standard of care option for patients with unresectable melanoma and have demonstrated benefit in the adjuvant setting [1,2].”
BackgroundMonoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17
Petrella, T. M., Fletcher, G. G., Knight, G. J., McWhirter, E., Rajagopal, S., Song, X., & Baetz, T. D. (2020) · Current Oncology · doi:10.3747/co.27.5933 · Cited by 17
The current state of adjuvant therapy of melanoma
Tarhini, A. A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30544-1 · Cited by 20
Current management of patients with melanoma who are found to be sentinel node‐positive
Nijhuis, A. A. G., Spillane, A. J., Stretch, J. R., Saw, R. P. M., Menzies, A. M., Uren, R. F., Thompson, J. F., & Nieweg, O. E. (2019) · ANZ Journal of Surgery · doi:10.1111/ans.15491 · Cited by 16
“The EORTC trial in stage III patients also demonstrated an improved recurrence-free survival with adjuvant pembrolizumab compared to placebo.(8) Results of the CheckMate 238 trial showed that recurrence-free survival with adjuvant nivolumab for 1 year was better than with ipilimumab in patients with stage IIIB, IIIC a…”
ResultAri, S. L., Serzan, M. T., Wu, T., Ip, A., Pascual, L., Sinclaire, B., Adams, S., Marafelias, M., Ayyagari, L., Gill, S. K., et al. (2023) · Cancer · doi:10.1002/cncr.34742 · Cited by 17
“African American 6 (2) 1 (1) 3 (3) 2 (1)”
Averbuch, I., Stoff, R., Miodovnik, M., Fenig, S., Bar‐Sela, G., Yakobson, A., Daliot, J., Asher, N., & Fenig, E. (2023) · Cancer Medicine · doi:10.1002/cam4.5890 · Cited by 18
Lin, A., Yao, J., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s394894 · Cited by 16
Combinational photodynamic and photothermal - based therapies for melanoma in mouse models
Lara-Vega, I., & Vega‐López, A. (2023) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2023.103596 · Cited by 16
Cellini, A., Scarmozzino, F., Angotzi, F., Ruggeri, E., Tos, A. P. D., Trentin, L., Pizzi, M., & Visentin, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203470 · Cited by 16
“Frontiers in Oncology 05 (CPI) in treating solid malignancies such as melanoma (63, 64) or non-small-cell lung cancer (65–67).”
BackgroundSun, W., Xu, Y., Yan, W., Wang, C., Hu, T., Luo, Z., Zhang, X., Liu, X. Z., & Chen, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6234 · Cited by 16
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
Silva, V., & Matos, C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03491-8 · Cited by 16
“Clinical trials have shown that pembrolizumab, as adjuvant therapy for high-risk stage III melanoma, resulted in significantly longer recurrence-free survival as compared to placebo, with no new toxic effects identified [91].”
Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study
Bloem, M., van Not, O. J., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers‐Sonderen, M. J., Bonenkamp, H. J., de Groot, J. B., Haanen, J. B. A. G., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35060 · Cited by 18
Self-citationEnzyme-catalyzed molecular MR imaging of tumors
Wu, Z., Yang, W., & Zhang, B. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117848 · Cited by 16
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Aung, T. N., Liu, M., Su, D. G., Shafi, S., Boyacı, C., Steen, S., Tsiknakis, N., Vidal, J. M., Maher, N. G., Micevic, G., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.18906 · Cited by 17
Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials
Ignacio, R. B., Lin, L. L., Rajdev, L. N., & Chiao, E. Y. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7064 · Cited by 16
Ipenburg, N. A., Thompson, J. F., Uren, R. F., Chung, D. K. V., & Nieweg, O. E. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07505-6 · Cited by 16
Surgical Considerations and Systemic Therapy of Melanoma
Gamboa, A. C., Lowe, M., Yushak, M. L., & Delman, K. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.012 · Cited by 17
Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma
Read, R. L., & Thompson, J. F. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1689121 · Cited by 16
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy
Zubiri, L., Allen, I. M., Taylor, M. S., Guidon, A. C., Chen, S. T., Schoenfeld, S. R., Neilan, T. G., Sise, M. E., Mooradian, M. J., Rubin, K. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0883 · Cited by 16
Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma
Stellato, D., Thabane, M. E., Eichten, C., & Delea, T. E. (2019) · Current Oncology · doi:10.3747/co.26.5085 · Cited by 17
Hanks, J. E., Kovatch, K. J., Ali, S. A., Roberts, E., Durham, A. B., Smith, J. D., Bradford, C. R., Malloy, K. M., Boonstra, P. S., Lao, C. D., et al. (2020) · Otolaryngology · doi:10.1177/0194599819899934 · Cited by 16
Immunotherapy for advanced melanoma: current situation in Japan
Kato, J., & Uhara, H. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa188 · Cited by 16
Farrow, N. E., Holl, E. K., Jung, J., Gao, J., Jung, S., Al-Rohil, R. N., Selim, M. A., Mosca, P. J., Ollila, D. W., Antonia, S. J., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09277-w · Cited by 16
Detection of cancer metastasis: past, present and future
Alix‐Panabières, C., Magliocco, A. M., Cortés‐Hernández, L. E., Eslami‐S, Z., Franklin, D., & Messina, J. L. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10088-w · Cited by 17
“Several studies have suggested that the pattern and burden of SLN tumor involvement may be linked to non-SLN positivity and clinical outcome measures [20, 21].”
BackgroundHigh-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
Quek, C. Y. J., Bai, X., Long, G. V., Scolyer, R. A., & Wilmott, J. S. (2021) · Genes · doi:10.3390/genes12101629 · Cited by 16
Self-citationThe Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma
Takabe, P., Siiskonen, H., Rönkä, A., Kainulainen, K., & Pasonen‐Seppänen, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.811434 · Cited by 18
Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis
Jin, Y., Wei, J., Weng, Y., Feng, J., Xu, Z., Wang, P., Cui, X. J., Chen, X., Wang, J., & Peng, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.732814 · Cited by 16
Saito, Y., Fujiwara, Y., Shinchi, Y., Mito, R., Miura, Y., Yamaguchi, T., Ikeda, K., Urakami, S., Nakashima, Y., Sakagami, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15442 · Cited by 18
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
Ng, G. K. H., Xu, W., & Atkinson, V. G. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01288-y · Cited by 17
“Pembrolizumab was compared with placebo in KEYNOTE-054 and included patients with stage IIIA (metastasis > 1 mm), IIIB and IIIC disease (AJCCv7) [7, 11].”
BackgroundMethodSelf-citationLonger survival from melanoma in Germany
Eisemann, N., Schumann, L., Baltus, H., Labohm, L., Kraywinkel, K., & Katalinic, A. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0242 · Cited by 16
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
Holmstroem, R. B., Pedersen, S., Jurlander, R. S., Madsen, K. S., Donia, M., Ruhlmann, C. H. B., Schmidt, H., Haslund, C. A., Bastholt, L., Svane, I. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114023 · Cited by 17
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16
Song, Y., Straker, R. J., Xu, X., Elder, D. E., Gimotty, P. A., Huang, A. C. C., Mitchell, T. C., Amaravadi, R. K., Schuchter, L. M., & Karakousis, G. C. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08174-1 · Cited by 16
Medina, B. D., Choi, B. H., Rodogiannis, K. G., Moran, U., Shapiro, R. L., Pavlick, A. C., Osman, I., Berman, R. S., & Lee, A. Y. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25987 · Cited by 16
Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma
Han, J., Xu, X., Liu, Z., Li, Z., Wu, Y., & Zuo, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106971 · Cited by 16
Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
Jang, S., Poretta, T., Bhagnani, T., Harshaw, Q., Burke, M. M., & Rao, S. A. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00404-9 · Cited by 16
Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review
Calvo, V., Sierra‐Rodero, B., Cruz‐Bermúdez, A., & Provencio, M. (2021) · Current Challenges in Thoracic Surgery · doi:10.21037/ccts-20-82 · Cited by 15
“(36), followed by nivolumab (37) and pembrolizumab (anti-PD-1) (38).”
BackgroundReschke, R., Gussek, P., & Ziemer, M. (2021) · Cancers · doi:10.3390/cancers13122902 · Cited by 15
Hidaka, Y., Arigami, T., Osako, Y., Desaki, R., Hamanoue, M., Takao, S., Kirishima, M., & Ohtsuka, T. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02661-8 · Cited by 15
Egeler, M., van Leeuwen, M., Fraterman, I., Heuvel, N. M. J. V. D., Boekhout, A. H., Lai-Kwon, J. E., Wilthagen, E. A., Eriksson, H., Haanen, J. B. A. G., Wilgenhof, S., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103919 · Cited by 15
Self-citationFacts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence
Vaidya, P., & Cohen, E. E. W. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0583 · Cited by 16
Tarhini, A. A., Eroglu, Z., Eljilany, I., Zager, J. S., González, R., Sarnaik, A. A., Cruse, C. W., Khushalani, N. I., Aquino, D. B. D., Abraham, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2768 · Cited by 19
Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M. S., Ferrone, S., Formenti, S. C., Gajewski, T. F., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1979-z · Cited by 16
Self-citationDifferential risks of immune-related colitis among various immune checkpoint inhibitor regimens
Yao, J., Li, M., Zhang, H., Ge, Y., Weygant, N., & An, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106770 · Cited by 15
Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma
Aiken, T. J., Stahl, C. C., Schwartz, P. B., Barrett, J. R., Acher, A. W., Lemaster, D. M., LEVERSON, G. E., Weber, S. M., Neuman, H. B., & Abbott, D. E. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26225 · Cited by 15
Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 15
Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells
Strobel, S. B., Machiraju, D., Hülsmeyer, I., Becker, J. C., Paschen, A., Jäger, D., Wels, W. S., Bachmann, M. P., & Hassel, J. C. (2021) · Life · doi:10.3390/life11040269 · Cited by 15
“In melanoma, immunotherapies with immune checkpoint blockers made it possible to even cure patients [1,2].”
BackgroundLivingstone, A., Milne, D., Dempsey, K., Muscat, D. M., Menzies, A. M., Howard, K., Stockler, M. R., & Morton, R. L. (2021) · Patient · doi:10.1007/s40271-021-00507-1 · Cited by 15
Koelblinger, P., Hoellwerth, M., Dernoscheg, M., Koch, L., Richtig, E., Wanner, M., Nguyen, V., Ostermann, H., Bauer, J. W., & Laimer, M. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14511 · Cited by 15
Smithers, B. M., Saw, R. P. M., Gyorki, D. E., Martin, R. C. W., Atkinson, V. G., Haydon, A. M., Roberts‐Thomson, R., & Thompson, J. F. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.17051 · Cited by 17
Self-citationChoi, B., & Kim, D. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100010 · Cited by 15
Rossi, E., Schinzari, G., Maiorano, B. A., Esposito, I., Acampora, A., Romagnoli, J., Stefani, A. D., Regno, L. D., Lancellotta, V., Fionda, B., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0195 · Cited by 17
Andersen, J. A. S., Spatzek, A. D., Vilstrup, M. H., Grupe, P., Hess, S., Holdgaard, P. C., Bastholt, L., Gerke, O., & Hildebrandt, M. G. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05704-0 · Cited by 18
Fujiwara, Y., Horita, N., Harrington, M. D., Namkoong, H., Miyashita, H., & Galsky, M. D. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03203-7 · Cited by 15
Chen, S., Zhang, S., Wang, Z., Li, J., Yuan, Y., Li, T., Zuo, M., Feng, W., Li, W., Chen, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1038272 · Cited by 17
“Immunotherapy, targeting the defense effects of the immune system to attack tumor cells, has made breakthroughs in multiple cancers (Eggermont et al., 2018; Gandhi et al., 2018; Choueiri et al., 2021; Cortes et al., 2022).”
BackgroundZhang, J., Quadri, S. A., Wolfgang, C. L., & Zheng, L. (2018) · Biomedicines · doi:10.3390/biomedicines6030087 · Cited by 18
An Update on Adjuvant Systemic Therapies in Melanoma
Samuel, E., Moore, M. A., Voskoboynik, M., Shackleton, M. J., & Haydon, A. M. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0009 · Cited by 16
Self-citationZhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895753 · Cited by 20
Gerbasi, M. E., Stellato, D., Ghate, S. R., Ndife, B. C., Moynahan, A., Mishra, D., Gunda, P., Koruth, R., & Delea, T. E. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1635487 · Cited by 16
Jochems, A., Bastiaannet, E., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., Boers‐Sonderen, M. J., van den Eertwegh, A. J. M., de Glas, N. A., de Groot, J. W. B., Haanen, J. B. A. G., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.04.006 · Cited by 14
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
Cristinziano, L., Modestino, L., Capone, M., Madonna, G., Mallardo, D., Giannarelli, D., D’Angelo, G., Ferrara, A. L., Loffredo, S., Varricchi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962669 · Cited by 16
“Finally, since stage III melanoma patients are currently considered candidates for anti-PD-1 therapy (4, 57), it would be necessary to assess whether PD-L1 PMNs predict clinical outcomes in patients other than stage IV melanoma.”
BackgroundSelf-citationZhao, P., Zhao, T., Yu, L., Ma, W., Liu, W., & Zhang, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1381250 · Cited by 18
Luke, J. J., Long, G. V., Robert, C., Carlino, M. S., Choueiri, T. K., Haas, N. B., O’Brien, M., Paz-Ares, L. G., Peters, S., Powles, T. B., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114146 · Cited by 14
Self-citationÖzkan, A., Kapiteijn, E., van den Bos, F., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C., Bloem, M., Blokx, W. A. M., Boers‐Sonderen, M. J., Bonenkamp, J. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115056 · Cited by 15
“In our population, grade ≥ 3 irAEs were observed in 15.0 % of the patients, which is consistent with findings from earlier adjuvant trials, such as the 14.4 % reported in the Checkmate-238 trial and the 14.7 % in the EORTC 1325/Keynote-054 trial [5,22].”
InfluentialSelf-citationFonseca, I. B., Lindote, M. V. N., Monteiro, M. R., Filho, E. D., Pinto, C. A. L., Jafelicci, A. S., Lobo, M. D. M., Calsavara, V. F., Bertolli, E., & Neto, J. P. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08959-9 · Cited by 15
Holstead, R. G., Kartolo, B., Hopman, W. M., & Baetz, T. D. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000736 · Cited by 14
Tian, Y., Li, R., Liu, Y., Li, M., Song, Y., Zheng, Y., Gao, A., Wen, Q., Su, G., & Sun, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667650 · Cited by 14
“The corresponding funnel plot was shown in the supplement (Supplementary Figure 5B) (28, 29).”
BackgroundMethodBlaise, M., Rocher, F., Spittler, H., Sanchez, A., Lantéri, E., Coco, L., Puma, A. R., Martel, A., Gonfrier, G., Passeron, T., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17760 · Cited by 14
Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
Dietz, H., Weinmann, S. C., & Salama, A. K. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s283217 · Cited by 18
Broman, K. K., Richman, J., & Bhatia, S. (2022) · Surgery · doi:10.1016/j.surg.2021.12.025 · Cited by 15
Lodde, G. C., Zimmer, L., Livingstone, E., Schadendorf, D., & Ugurel, S. (2019) · Der Hautarzt · doi:10.1007/s00105-019-04514-0 · Cited by 35
Self-citationNovel Biomarkers and Therapeutic Targets for Melanoma
Sabag, N., Yakobson, A., Retchkiman, M., & Silberstein, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911656 · Cited by 14
“PD1-inhibitor monotherapy has already been proven as an efficient treatment for unresectable melanoma [45] and as an adjuvant therapy for stage III melanoma [46] regardless of PDL1 expression levels.”
BackgroundChen, S., Zhang, S., Feng, W., Li, J., Yuan, Y., Li, W., Wang, Z., Yang, Y., & Liu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072253 · Cited by 22
“Immunotherapy, emerging under the spotlight as a novel therapy for cancers, has been proven effective in multiple types of cancer (Eggermont et al., 2018; Gandhi et al., 2018; Choueiri et al., 2021b; Cortes et al., 2022).”
Background
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.